Abstract

Efficacy of Rheocarna^® in no-option chronic limb-threatening ischemia

Author(s): Akinori Satake, Takahiro Tokuda, Hirofumi Ohashi, Tetsuya Amano

In 2021, a new low-density lipoprotein apheresis device (Rheocarna®; Kaneka Corporation, Osaka, Japan) was developed in Japan for treating Chronic Limb T hreatening Ischemia (CLTI) with refractory ulcers (Rutherford classification score, 5 or 6), referred to as no-option CLTI. This device eliminates key contributors to CLTI such as Low-Density Lipoprotein Cholesterol (LDL-C) and fibrinogen. Rheocarna® therapy might enhance skin perfusion pressure, reduce LDL-C, fibrinogen, and C-reactive protein levels, and improve acute-phase angiography findings, leading to better microcirculation and wound healing and help maintain chronic-phase blood microcirculation and wound healing. This study demonstrates that Rheocarna® may be a viable treatment option for no-option CLTI.